Researchers report a drug discovery strategy using tailor-made cyclic peptides to target β-arrestins, key regulators of ...

Over the past decade, however, a wave of technological advances has begun to expand the druggable proteome. These include covalent inhibitors (such as sotorasib), chemical proteomics, and AI-enabled ...

FUJIFILM Corporation announces the successful validation of the cancer cell-targeting potential of its peptide-oligonucleotide conjugates. This validation resulted from combining oligonucleotides with ...

BEIJING, Jan. 8, 2025 /PRNewswire/ -- In a recent achievement, DP Technology's hit discovery platform RiDYMO® has successfully designed a cyclic peptide targeting β-catenin, a historically ...

The farnesoid X receptor (FXR) is a bile acid nuclear receptor that plays a crucial role in regulating bile acid and sterol metabolism. Bile acids are natural ligands of FXR, which bind to the ...

Drug discovery demands speed and precision, with success often hinging on how quickly teams can move compounds through synthesis, purification, and testing. In this project, flexibility and agility ...

Orbis Medicines emerged from stealth Feb. 29 with $28 million in seed funding. The company is the latest launched to turn cyclic peptide molecules into orally available drugs that could replace ...

The farnesoid X receptor (FXR) is a bile acid nuclear receptor that plays a crucial role in regulating bile acid and sterol metabolism. Bile acids are natural ligands of FXR, which bind to the ...

For decades, a substantial number of proteins, vital for treating various diseases, have remained elusive to oral drug therapy. Traditional small molecules often struggle to bind to proteins with flat ...